Aβ antibody 4g8

Manufactured by BioLegend

The Aβ antibody (4G8) is a monoclonal antibody that recognizes the amyloid-beta (Aβ) protein. This antibody is specific for the amino acid sequence 17-24 of the Aβ peptide.

Automatically generated - may contain errors

Lab products found in correlation

Ez link nhs peg4 biotin kit, by Thermo Fisher Scientific (1 mentions) Lsrii flow cytometer, by FlowJo (1 mentions) Ethylene diamine tetraacetic acid (edta), by Avantor (1 mentions)

Close spelling variants of this product

Anti-Aβ 4G8 antibody Mouse anti-Aβ 4G8 antibody Aβ (4G8, 4G8 antibody

3 protocols using aβ antibody 4g8

Erythrocyte-bound Amyloid-Beta Quantification

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Aβ antibody 4G8 (BioLegend, San Diego, CA) and mouse isotype control IgG (Thermo Fisher Scientific) were biotinylated using the EZ-Link NHS-PEG4 Biotin kit (Thermo Fisher Scientific) following the manufacturer’s instructions. Erythrocyte membrane samples from the prospectively-enrolled 80 AD and 117 ND cases were incubated with the biotinylated antibodies and assayed for Aβ using conventional flow cytometry methods we have previously published [26 (link)] (see also Supplementary Material). A minimum of 10,000 events/sample were recorded on a Becton-Dickinson LSR II flow cytometer and analyzed for Aβ capture with FlowJo v10.1 (FlowJo, Ashland, OR).

Johansson J.U., Brubaker W.D., Javitz H., Bergen A.W., Nishita D., Trigunaite A., Crane A., Ceballos J., Mastroeni D., Tenner A.J., Sabbagh M, & Rogers J. (2018). Peripheral complement interactions with amyloid β peptide (Aβ) in Alzheimer’s disease: polymorphisms, structure, and function of complement receptor 1. Alzheimer's & dementia : the journal of the Alzheimer's Association, 14(11), 1438-1449.

+ Open protocol

+ Expand

Amyloid Plaque Imaging Protocol

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

All samples were retrieved from archives of the University of California, Davis Alzheimer’s Disease Center (UCD-ADC) Brain Bank. Archival samples analyzed in this study were 5 μm formalin fixed, paraffin embedded, sections of the superior and middle temporal gyrus. The tissue had been previously stained with an Aβ antibody (4G8, recognizing residues 17–24, dilution 1:1600, BioLegend (formally Covance), catalog number SIG-39200) that were first pretreated with formic acid to rid samples of endogenous protein. All slides were digitized using an Aperio AT2 up to ×40 magnification. Supplementary Table 1 details overall NIA Reagan criteria⁶⁵, CAA type^{66 (link)} 1 or 2 within the section, and Thal Amyloid phase^{5 (link)} of these cases.
Procedures were in accordance with ethical standards of the Helsinki Declaration. Operations of the University of California Davis Alzheimer’s Disease Center was approved by the Institutional Review Board (IRB) of the University of California Davis, and written consent for autopsy was obtained for each participant during life. Details of this program have been previously published^{67 (link)}.

Tang Z., Chuang K.V., DeCarli C., Jin L.W., Beckett L., Keiser M.J, & Dugger B.N. (2019). Interpretable classification of Alzheimer’s disease pathologies with a convolutional neural network pipeline. Nature Communications, 10, 2173.

+ Open protocol

+ Expand

Aβ Complement Activation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Various concentrations of Aβ prepared in 100 mM Tris, as above, were incubated with either Aβ antibody (4G8, Biolegend, San Diego, CA) or PBS, pH 7.2, after which the solutions were mixed with normal human serum (NHS) (CompTech, Tyler, Texas) for 30 minutes at 37°C. NHS plus 10 mM EDTA (Amresco, Solon, OH) (final concentration in the serum) was employed as a control. C3a production, one of several standard measures of complement activation, was assayed by ELISA (Affymetrix, Santa Clara, CA, #BHS2089) following the manufacturer’s protocol.

Crane A., Brubaker W.D., Johansson J.U., Trigunaite A., Ceballos J., Bradt B., Glavis-Bloom C., Wallace T.L., Tenner A.J, & Rogers J. (2017). Peripheral complement interactions with amyloid β peptide (Aβ) in Alzheimer’s disease: 2. Relationship to Aβ immunotherapy. Alzheimer's & dementia : the journal of the Alzheimer's Association, 14(2), 243-252.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!